The R&D Day is scheduled for
Pierluigi Porcu , M.D., Professor of Medical Oncology, Director of theDivision of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation ,Department of Medical Oncology atThomas Jefferson University Robert A. Baiocchi , M.D., Ph.D., Professor of Internal Medicine, Associate Director for Translational and Clinical Science in theDivision of Hematology atThe Ohio State University
A live video webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for at least 30 days following the event.
About
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Head of Investor Relations & Corporate Communications
abarreto@viracta.com
SOURCE
Source:
2023 GlobeNewswire, Inc., source